An interventional study of Masimo MightySat Rx in RRP (Respiration Rate From PPG), sponsored by Masimo Corporation. Completed. Open to participants aged 5 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Masimo Corporation (part of Danaher Corporation) · Interventional and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective, non-randomized data collection study to evaluate the clinical performance of the Masimo MightySat Rx in pediatric populations.
32 studies on the registry are indexed under Recurrent respiratory papillomatosis; 9 are open to participants now.
This study's enrollment of 40 is above the median of 27 across 23 interventional studies indexed under Recurrent respiratory papillomatosis.
Browse Recurrent respiratory papillomatosis studies →Masimo Corporation is the lead sponsor of 106 studies on the registry; 1 is open to participants now.
Of its 79 completed or terminated interventional studies of FDA-regulated products, 67 (85%) have results posted.
First submitted before Masimo Corporation became part of Danaher Corporation.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All subjects are enrolled into this arm and will have respiratory measurements obtained.
Device: Masimo MightySat Rx
Masimo MightySat Rx will be used to measure respiratory values.
RRp (Respiration Rate From PPG) Performance of MightySat Rx in Pediatric Populations Meets Its Performance Specifications.
The outcome measure is the determination of MightySat Rx performance by calculating the Mean Error and ARMS value through the comparison of RRp obtained by MightySat Rx against the reference (RRref) based on capnography. Mean Error = (∑(i=1 to n) ((RRP\_i-RRref\_i ))/n. Arms= √(∑(i=1 to n) ((RRP\_i-RRref\_i )\^2 ))/n.
Time frame: Approximately 15 minutes
| Milestone | MightySat Rx |
|---|---|
| Started | 40 |
| Completed | 40 |
| Not completed | 0 |
The outcome measure is the determination of MightySat Rx performance by calculating the Mean Error and ARMS value through the comparison of RRp obtained by MightySat Rx against the reference (RRref) based on capnography. Mean Error = (∑(i=1 to n) ((RRP\_i-RRref\_i ))/n. Arms= √(∑(i=1 to n) ((RRP\_i-RRref\_i )\^2 ))/n.
| RPM (Respirations per minute) | MightySat Rx |
|---|---|
| Mean Error | -0.51 |
| ARMS | 2.08 |
Collected over Approximately 15 minutes. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MightySat Rx | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Age, Categorical(Participants) | MightySat Rx |
|---|---|
| <=18 years | 40 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | MightySat Rx |
|---|---|
| Female | 22 |
| Male | 18 |
| Race (NIH/OMB)(Participants) | MightySat Rx |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 7 |
| White | 27 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2023 to primary completion in Jul 2023, 2 months.
Results were first posted in Nov 2026, 3 years 4 months after primary completion. A results delay was requested in Aug 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Recurrent respiratory papillomatosis →